Literature DB >> 1310235

Cardiovascular and renal actions of C-type natriuretic peptide.

A J Stingo1, A L Clavell, L L Aarhus, J C Burnett.   

Abstract

Studies were performed in two groups of anesthetized dogs (n = 5 per group) to determine the cardiovascular and renal actions of synthetic C-type natriuretic peptide (CNP). Systemic infusion of CNP (group 1; 10 and 50 ng.kg-1.min-1 iv) resulted in marked cardiovascular hemodynamic effects characterized by a decrease in mean arterial pressure, cardiac output, and atrial pressures in association with a decrease in sodium excretion. Bolus administration of CNP (group 2; 5 micrograms/kg iv) to minimize cardiovascular hemodynamic changes resulted in only a transient decrease in arterial pressure. Sodium excretion decreased despite a return of arterial pressure to baseline. These biological responses were associated with increases in plasma guanosine 3',5'-cyclic monophosphate (cGMP) in both groups but with no change in urinary cGMP. With both systemic infusion or bolus administration of CNP, significant increases in plasma aldosterone were observed in association with increases in distal nephron sodium reabsorption. This study demonstrates that CNP exhibits profound systemic hemodynamic actions and is indirectly, or perhaps directly, antinatriuretic.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1310235     DOI: 10.1152/ajpheart.1992.262.1.H308

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  31 in total

1.  Glycosylation of asparagine 24 of the natriuretic peptide receptor-B is crucial for the formation of a competent ligand binding domain.

Authors:  R Fenrick; N Bouchard; N McNicoll; A De Léan
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

2.  C-type natriuretic peptide stimulates ovarian follicle development.

Authors:  Yorino Sato; Yuan Cheng; Kazuhiro Kawamura; Seido Takae; Aaron J W Hsueh
Journal:  Mol Endocrinol       Date:  2012-05-17

3.  Relaxing With C-Type Natriuretic Peptide, the Guanylyl Cyclase B Receptor, and Pericytes.

Authors:  S Jeson Sangaralingham; John C Burnett
Journal:  Circulation       Date:  2018-07-31       Impact factor: 29.690

Review 4.  Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.

Authors:  Ruth Hsiao; Barry Greenberg
Journal:  Curr Heart Fail Rep       Date:  2016-08

Review 5.  Coronary endothelial function in health and disease.

Authors:  J C Burnett
Journal:  Drugs       Date:  1997       Impact factor: 9.546

6.  The Role of Neprilysin Inhibitors in Cardiovascular Disease.

Authors:  Jared Mills; Orly Vardeny
Journal:  Curr Heart Fail Rep       Date:  2015-12

7.  C-type natriuretic peptide levels in cor pulmonale and in congestive heart failure.

Authors:  R I Cargill; C S Barr; W J Coutie; A D Struthers; B J Lipworth
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

8.  Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide.

Authors:  C M Wei; C H Kim; V M Miller; J C Burnett
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B.

Authors:  Thomas H Langenickel; Jens Buttgereit; Ines Pagel-Langenickel; Maren Lindner; Jan Monti; Knut Beuerlein; Nidal Al-Saadi; Ralph Plehm; Elena Popova; Jens Tank; Rainer Dietz; Roland Willenbrock; Michael Bader
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-14       Impact factor: 11.205

10.  Direct chronotropic effects of atrial and C-type natriuretic peptides in anaesthetized dogs.

Authors:  P Beaulieu; R Cardinal; A De Léan; C Lambert
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.